Empagliflozin as Add-On to Metformin for 24 Weeks in Patients with Type 2 Diabetes

Trial Profile

Empagliflozin as Add-On to Metformin for 24 Weeks in Patients with Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2015 Results (pooled analysis of four, 24 week, phase III trials - NCT01159600, NCT01719003, NCT01778049, 3090558) presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 23 Jul 2013 New trial record
    • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top